2024-510972-19-00招募中2 期
Axicabtagene Ciloleucel CAR T-Cells in Patients with relapsed or refractory primary mediastinal B-Cell Lymphoma
Universitaet Muenster23 个研究点 分布在 1 个国家目标入组 40 人开始时间: 2025年2月7日最近更新:
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 40
- 试验地点
- 23
- 主要终点
- CMR rate at 3 months from axicabtagene ciloleucel infusion based on disease assessment by PET-CT or PET-MRI according to Deauville and Lugano Classification
研究概览
简要总结
Evaluate the efficacy of axicabtagene ciloleucel in subjects with r/r PMBCL as measured by complete metabolic response (CMR) rate
入排标准
- 年龄范围
- 18 years 至 64 years（18-64 Years）
- 接受健康志愿者
- 否
入选标准
- •1.Signed written informed consent form (ICF)
- •Age > 18 years
- •ECOG performance status < 2
- •Histologically confirmed primary mediastinal B-cell lymphoma (PMBCL) • based on the 2022 World Health Organization (WHO) (R. Allagio et al.) • classification by local pathology laboratory assessment
- •Patients must have received adequate first-line therapy including: • An anti-CD20 monoclonal antibody (rituximab), and • CHOP or CHOP-like chemotherapy Note: CHOP-like chemotherapy corresponds to CHOEP, ACVBP or EPOCH or COPADEM. Patients who received dose-reduced CHOP (e.g., mini-CHOP) are excluded except for dose reductions of vincristine due to peripheral neuropathy. Patients who have received additional drugs in combination with CHOP or CHOP-like regimen are eligible.
- •Relapsed or refractory disease after first-line chemoimmunotherapy, documented by PET-CT: • Relapsed disease defined as complete remission to first-line therapy followed by biopsy-proven relapse • Refractory disease defined as: Progressive disease (PD) during first-line therapy Stable disease (SD) as best response after at least 4 cycles of first-line therapy (e.g., 4 cycles of R-CHOP) and biopsy-proven residual disease, or Partial response (PR) as best response after at least 6 cycles, and biopsy-proven residual disease
- •At least 2 weeks must have elapsed since any prior systemic cancer therapy at the time the patient provides consent
- •Lymphoma tissue at recurrence available for central pathologic examination, exploratory endpoints, and ancillary studies (detailed sample collection requirements are described in protocol section 8.2)
- •Patients must have at least 1 measurable lesion per the Lugano Classification on anatomical imaging such as computed tomography (CT) imaging (functional imaging such as PET may not be used to identify a measurable lesion). A measurable lesion is defined as greater than 1.5 cm LDi for lymph node and greater than 1.0 cm LDi for extranodal lesions
- •Patients must be eligible for CAR T-cells as defined by: • Patient deemed eligible for CAR T-cells therapy by the study physician • Adequate vascular access for leukapheresis procedure (either peripheral or central venous line)
- •Adequate bone marrow, renal, hepatic, cardiac and pulmonary function defined as: • Absolute neutrophil count (ANC) ≥ 1000 cells/μL • Absolute lymphocyte count > 100/μL • Platelets ≥ 75,000 cells/μL • Creatinine clearance (as estimated by Cockcroft Gault) ≥ 40 ml/min • Transaminases (AST and ALT) <2.5 x ULN • Total bilirubin < 1.5 x ULN unless other reason known (Gilbert-Meulengracht-Syndrome in which 3 x ULN would be acceptable) • Left ventricular ejection fraction (LVEF) ≥ 40% and no evidence of clinically significant pericardial effusion, and no significant abnormal electrocardiogram (ECG) findings • Baseline oxygen saturation > 92% on room air
- •Females of childbearing potential (FCBP) must have a negative serum or urine pregnancy test (females who have undergone surgical sterilization or who have been postmenopausal for at least 12 months are not considered to be of childbearing potential)
- •Sexually active men and FCBP must agree to use one of the highly effective contraceptive methods (combined oral contraceptives using two hormones, contraceptive implants, injectables, intrauterine devices, sterilized partner) together with one of the barrier methods (latex condoms, diaphragms, contraceptive caps) while on study; this should be maintained for 12 months after the last dose of study drug
- •Willingness not to drive a vehicle for 8 weeks post CAR T-cell treatment
排除标准
- •Patients who received more than one prior line of systemic therapy
- •Prior CD19-targeted therapy
- •History of another primary malignancy that has not been in remission for at least 2 years (except for non-melanoma skin cancer or carcinoma in situ (e.g., cervix, bladder, breast)). A maintenance treatment is not allowed
- •History or presence of non-malignant CNS disorder, such as seizure disorder requiring anti-convulsive therapy, cerebellar disease, any autoimmune disease with CNS involvement, posterior reversible encephalopathy syndrome (PRES), or cerebral edema with confirmed structural defects by appropriate imaging. History of stroke or transient ischemic attack within 12 months prior to enrollment. • Secondary CNS involvement of PMBCL is not an exclusion criterion
- •History of acute or chronic active hepatitis B or C infection. If there is a positive history of treated hepatitis B or hepatitis C, the viral load must be undetectable per quantitative polymerase chain reaction (PCR) and/or nucleic acid testing
- •Positive for human immunodeficiency virus (HIV) unless taking appropriate anti-HIV medications, with an undetectable viral load by PCR and with a CD4 count > 200 cells/µl
- •Presence of any indwelling line or drain (e.g., percutaneous nephrostomy tube, indwelling Foley catheter, biliary drain, or pleural/peritoneal catheter). Dedicated venous access catheters, such as a Port-a-Cath or Hickman catheter, are permitted
- •Uncontrolled systemic fungal, bacterial, viral or other infection despite appropriate antimicrobials at the time of enrollment
- •Presence of cardiac atrial or ventricular lymphoma involvement
- •History of any one of the following cardiovascular conditions within the past 12 months: Class III or IV heart failure as defined by the New York Heart Association, cardiac angioplasty or stenting, myocardial infarction, unstable angina, or other clinically significant cardiac disease
- •History of any medical condition including but not limited to autoimmune disease (e.g., Crohn’s disease, rheumatoid arthritis, systemic lupus) requiring systemic immunosuppression and/or systemic disease modifying agents within the last year. Endocrine conditions that require maintenance with physiologic dose steroids are allowed
- •History of idiopathic pulmonary fibrosis, organizing pneumonia (e.g., bronchiolitis obliterans), drug-induced pneumonitis, idiopathic pneumonitis, or evidence of active pneumonitis per chest computed tomography (CT) scan at screening. History of radiation pneumonitis in the radiation field (fibrosis) is allowed
- •History of severe immediate hypersensitivity reaction to any of the agents used in this study, including aminoglycosides, cyclophosphamide, fludarabine or tocilizumab
- •Treatment with a live, attenuated vaccine within 6 weeks prior to initiation of study treatment or anticipation of need for such a vaccine during the study
- •FCBP who are pregnant or breastfeeding
- •In the investigator’s judgment, the patient is unlikely to complete all protocol-required study visits or procedures, including follow-up visits, or comply with the study requirements for participation
- •Adult person unable to provide informed consent because of intellectual impairment, any serious medical condition, laboratory abnormality or psychiatric illness.
- •Simultaneously active participation in another clinical trial involving an IMP within 30 days prior to enrolment into this clinical trial
- •Patients with a physical or psychiatric condition which at the investigator’s discretion may put the patient at risk, may confound the trial results, or may interfere with the patient’s participation in this clinical trial
- •Known or persistent abuse of medication, drugs or alcohol
- •Primary immunodeficiency
- •Any medical condition likely to interfere with assessment of safety or efficacy of study treatment
- •Any psychological, familial, sociological, or geographical condition potentially hampering compliance with the study protocol and follow up schedule
结局指标
主要结局
CMR rate at 3 months from axicabtagene ciloleucel infusion based on disease assessment by PET-CT or PET-MRI according to Deauville and Lugano Classification
CMR rate at 3 months from axicabtagene ciloleucel infusion based on disease assessment by PET-CT or PET-MRI according to Deauville and Lugano Classification
次要结局
未报告次要终点
研究者
Georg Lenz
Scientific
Universitaet Muenster
研究点 (23)
Loading locations...
相似试验
招募中
2 期
A clinical trial to learn about the effects of YTB323 in people with difficult to treat severe diffuse cutaneous systemic sclerosis (dcSSc)2023-510380-34-00Novartis Pharma AG72
招募中
2 期
Evaluation of the efficacy and safety of Rituximab in patients with Amyotrophic Lateral Sclerosis (ALS)2022-502743-35-00Deutsches Zentrum Fuer Neurodegenerative Erkrankungen e.V.52
尚未招募
1 期
CAR-T for Claudin18.2 Positive Solid TumorsNCT07266311Chengdu Ucello Biotechnology Co., Ltd.18
招募中
2 期
Frontline Asciminib combination in chronic phase CML2024-516212-24-00Friedrich-Schiller-Universitaet Jena125
尚未招募
1 期
CD19/BCMA CAR-T for SLENCT07266337Chengdu Ucello Biotechnology Co., Ltd.24